This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| ICD-10 | G71.0 |
| Special Copayment Reduction | V012 · 5 years |
| A. Synonyms | Oculopharyngeal muscular dystrophy |
| B. Adult onset | High — typically onset after the 50s; mean age at symptom onset 48~60 years |
| 1. History | First described by Taylor in 1915 as a familial muscle disease with ptosis and dysphagia; 1962 Victor et al. established the name OPMD; 1998 discovery of the GCG repeat expansion mutation in the PABPN1 gene |
| 2. Causes | GCG trinucleotide repeat expansion in the PABPN1 gene (14q11.2-q13); normal 10 repeats → pathological 12~17 repeats (dominant); homozygous or compound heterozygous 11~12 repeats (recessive) |
| 3. Genetics | Typically autosomal dominant; rarely autosomal recessive (11~12 repeats); founder effects in the Spanish Canadian Boucanville population and in Ashkenazi Jews |
| 4. Epidemiology | Europe about 1/100,000; Spanish Canadians 1/1,000; Ashkenazi Jews 1/600; no accurate statistics on incidence in Korea |
| 5. Pathophysiology | Expanded polyalanine PABPN1 protein forms insoluble intranuclear inclusions (INI) → loss of normal PABPN1 function (frame effect and gain-of-function) → myonuclear dysfunction |
| 6. Symptoms | Ptosis (initial symptom, unilateral or bilateral) → dysphagia (both liquids and solids) → proximal limb weakness; ocular motility disorder is rare |
| 7. Signs | Ptosis, forehead wrinkling (compensatory), soft palate weakness, gastroesophageal reflux, risk of aspiration pneumonia; intranuclear inclusions (INI) on muscle biopsy are characteristic |
| 8. Screening | PABPN1 gene repeat number testing in adults with a family history and a combination of ptosis and dysphagia; family screening by blood genetic testing |
| 9. Diagnosis | PABPN1 gene repeat number analysis (PCR/Southern blot) → muscle biopsy (intranuclear inclusions on light microscopy, 8~10 nm filaments on electron microscopy); esophagography (assessment of swallowing function) |
| 10. Treatment | No curative treatment; ptosis — eyelid surgery (levator resection or frontalis suspension); dysphagia — cricopharyngeal myotomy, esophageal dilation, dietary adjustment; proximal weakness — physical therapy |
| 11. Prognosis | Slow rate of progression; walking ability mostly preserved; aspiration pneumonia is the main cause of death; aggressive surgical treatment can improve quality of life |
| 12. Prevention | Genetic counseling for familial clustering; regular monitoring after carrier identification; education on aspiration prevention; swallowing rehabilitation reduces complications |
| References | 10 key PMIDs/DOIs |
Oculopharyngeal Muscular Dystrophy (OPMD) first became known in 1915 when the American neurologist Taylor reported a French Canadian family with both ptosis and dysphagia. At the time, the genetic characteristics of the disease and its independent classification had not been established, but several researchers subsequently reported additional similar familial cases.
In 1962, Victor, Hayes and Adams analyzed families with the same phenotype and proposed the formal name "Oculopharyngeal Muscular Dystrophy." They established that the combination of ptosis and dysphagia due to pharyngeal muscle weakness, beginning in late adulthood, is a distinct entity of familial myopathy. Thereafter, as reports through the 1970s were concentrated mainly in French Canadian and Jewish populations, a founder effect was suspected.
The molecular genetic basis was established in 1998 when Brais et al. discovered that a GCG trinucleotide repeat expansion in the PABPN1 gene (then called PABP2) is the cause of OPMD. It was shown that the disease manifests when the GCG repeat, 10 in normal individuals, expands to 12~17, and this attracted attention because, unlike other trinucleotide repeat expansion diseases (Huntington disease, myotonic dystrophy, etc.), variation in repeat number is relatively stable and predictable.
Since the 2000s, there has been active research on the normal function of the PABPN1 protein, the mechanism of intranuclear inclusion (INI) formation, and preclinical studies of AAV-based gene therapy. In particular, a treatment strategy combining RNA interference (RNAi) and gene replacement has shown positive results in animal models, and progress toward clinical trials is under way.
OPMD is caused by a GCG trinucleotide repeat expansion in the PABPN1 (Poly(A) Binding Protein Nuclear 1) gene located on the long arm of chromosome 14 (14q11.2-q13). In normal individuals, GCG is repeated 10 times at the 5' end of PABPN1 exon 1, which is translated into 10 polyalanine residues. In OPMD, this repeat number increases to 12 or more, producing a polyalanine-expanded protein with 2~7 more residues than normal.
Dominant form (most patients): 12~17 GCG repeats, with an expansion mutation on one allele. The larger the repeat number, the earlier the age of onset and the more severe the clinical course tend to be. Recessive or mild dominant form: 11~12 repeats on both alleles, or a combination of 11 repeats (borderline range) on one allele and 12 or more on the other. In this case the phenotype is milder or the age of onset is later. On an allele with the normal repeat number of 10, the protein functions normally, and the mutant PABPN1 protein produced from the expanded allele forms toxic protein aggregates and is pathogenic.
The normal function of PABPN1 is to regulate the polyadenylation of mRNA precursors in the nucleus, control the length of the poly(A) tail and contribute to mRNA export and stability. Mutant PABPN1 loses these normal functions (loss-of-function) and at the same time forms intranuclear aggregates that cause toxic effects (gain-of-function).
OPMD typically follows an autosomal dominant mode of inheritance. Therefore, children of an affected parent have a 50% probability of inheriting the mutant allele and are at risk of developing the disease. Penetrance varies with age, but the rate of symptom onset by age 70~80 in mutation carriers is high, at more than 90%. However, with 12~13 repeats, clinical symptoms may still be faint in the 60s~70s.
Rarely, an autosomal recessive form is reported, in which both alleles carry 11~12 repeats; this has been identified particularly in Middle Eastern and Central Asian populations. In this case, heterozygous carriers (11~12 GCG repeats) are in the normal or borderline range and have no symptoms.
There are two populations in which a founder effect is clearly observed: (1) the Spanish Canadian Boucanville-lineage population — sharing a 13-GCG repeat, with the highest population incidence in the world, at about 1/1,000; (2) Ashkenazi Jews — sharing a 13-GCG repeat, with the second-highest incidence, at about 1/600. The mutations in these two populations are thought to have originated from independent founder events.
In genetic counseling, genetic testing is recommended for the patient's children and siblings, and regular clinical monitoring is started when an expanded repeat is confirmed. Because there is phenotypic variation (expressivity) according to repeat number even within the same family, it is difficult to predict the timing of onset and severity accurately from genetic test results alone.
The prevalence of OPMD in the general European population is estimated at about 1/100,000 (1 per 100,000 people). However, because of the founder effects described above, incidence is far higher in certain populations. Prevalence rates of about 1/1,000 in Spanish Canadian residents of Quebec and about 1/600 in Israeli Ashkenazi Jews have been reported. In addition, relatively high frequencies have been reported in France, Spain, Uruguay, the Middle East and parts of India.
Sex difference: OPMD affects men and women equally. The age of onset is typically in the 50s, and symptom onset is sometimes delayed until the 60s~70s. Onset before age 40 is rare, and the earlier the age of onset, the more often the repeat number is large or the patient is a recessive homozygote.
Situation in Korea: accurate epidemiological data on the prevalence of OPMD in Korea are still limited. It is partly included in other muscular dystrophies classified as G71.0 in rare disease statistics, but because statistics separated by detailed subtype are not systematically collected, it is difficult to determine the exact number of patients. It is likely to be clinically underdiagnosed, and when patients visit ophthalmology for ptosis or gastroenterology for dysphagia, OPMD should be kept in mind and family history and neuromuscular evaluation should be pursued together.
The PABPN1 protein normally participates in the 3'-end polyadenylation of mRNA precursors (pre-mRNA) in the nucleus. Specifically, together with poly(A) polymerase (PAP) it extends and regulates the poly(A) tail to a length of about 250 adenine residues and assists in exporting the completed mRNA to the cytoplasm. Through this, the efficiency of gene expression and mRNA stability are coordinated overall.
The mutant PABPN1 protein, whose polyalanine tract is lengthened by the GCG repeat expansion, tends to aggregate in the nucleus. The expanded polyalanine region reduces the stability of the protein's three-dimensional structure and forms insoluble intranuclear inclusions (INI). These INI are seen on electron microscopy as tubulofilament structures 8~10 nm in diameter and are found in about 2~3% of all myonuclei. Although the proportion of INI-positive myonuclei is low, they are a specific pathological finding of OPMD and have high diagnostic value.
In addition to mutant PABPN1, INI contain poly(A) RNA, RNA-binding proteins, components of the ubiquitin-proteasome system and other elements. This suggests that protein aggregation saturates the pathways that process abnormal proteins. The pathogenic mechanism is understood to involve a combination of (1) loss of function through sequestration of normal PABPN1, (2) nuclear dysfunction caused by the aggregates and (3) changes in mRNA expression due to abnormal polyadenylation. In animal models (mice and fruit flies), expression of mutant PABPN1 reproduced muscle weakness and INI formation, and overexpression of normal PABPN1 was confirmed to relieve symptoms, supporting the importance of the loss-of-function mechanism.
The clinical symptoms of OPMD appear gradually and consist of three main components: (1) ptosis, (2) dysphagia and (3) proximal limb weakness. These three symptoms do not necessarily appear simultaneously but develop sequentially or at intervals.
Ptosis is the first symptom to appear, mostly starting on one side and progressing to both sides. The eyelids gradually droop and obstruct vision, and patients contract the frontalis muscle to form horizontal forehead wrinkles or adopt a compensatory posture of tilting the head back and looking down. Abnormal eye movement (external ophthalmoplegia) is characteristically absent in OPMD, a key point in clinically distinguishing oculopharyngeal muscular dystrophy from ophthalmoplegia due to mitochondrial disease (PEO, chronic progressive external ophthalmoplegia).
Dysphagia is the second symptom to appear; initially swallowing solid food is difficult, and with progression drinking liquids also becomes difficult. Weakness of the pharyngeal muscles and the levator veli palatini causes food to regurgitate into the nasopharynx and increases the risk of aspiration from residue after swallowing. Prolonged mealtimes, coughing after meals, weight loss and aspiration pneumonia occur secondarily. It is not uncommon for dysphagia to appear before ptosis.
Proximal limb weakness often appears decades after onset and mainly affects the proximal shoulder and pelvic muscles. Most patients maintain independent walking throughout life, and cardiomyopathy is not a major clinical feature of OPMD.
Physical examination findings: bilateral or unilateral ptosis (levator muscle weakness), forehead wrinkling (compensatory), reduced palpebral aperture exposure. Eye movements are normal in all directions, and this is the key sign distinguishing OPMD from mitochondrial extraocular muscle disease. Reduced gag reflex, reduced soft palate movement and nasal speech may be observed. Videofluoroscopic swallowing study (VFSS) shows reduced pharyngeal contraction, pharyngeal residue and aspiration.
Muscle biopsy findings: on conventional light microscopy (H&E staining), variation in muscle fiber size, internalized nuclei and intranuclear inclusions (INI) are observed. Gomori modified trichrome (GMT) staining shows rimmed vacuoles. Identification on electron microscopy of intranuclear tubulofilament aggregates 8~10 nm in diameter is the pathological confirmatory finding of OPMD. INI can also be detected by immunofluorescence using anti-PABPN1 antibodies.
Serum CK: a mild elevation (2~10 times normal) is common, but there are cases without a clear CK rise, so a normal CK does not exclude OPMD. Electromyography shows myopathic changes (small polyphasic motor unit potentials), but these are nonspecific. Nerve conduction studies are normal.
Screening for OPMD begins with recognition of the clinical symptom pattern and confirmation of the family history. When unexplained ptosis appears after the 50s, especially with concurrent dysphagia or a family member with similar symptoms, OPMD should be actively suspected. A multidisciplinary system in which patients presenting to ophthalmology or otolaryngology with ptosis or dysphagia are referred to neurology for neuromuscular evaluation is important.
Family screening: PABPN1 gene repeat number analysis is offered to first-degree relatives (parents, siblings, children) of patients confirmed with OPMD. Even if asymptomatic, regular follow-up (assessment of swallowing function and ptosis every 1~2 years) is performed when a mutation is confirmed. Serum CK measurement often shows a mild elevation and can be used as an adjunct in screening. Because its sensitivity and specificity alone are low, it is more efficient to proceed directly to genetic testing when clinically suspected.
In populations with known founder effects (patients of Quebec descent residing in France, Ashkenazi Jews, and patients from certain Middle Eastern regions), the relative frequency of OPMD is high, so routine OPMD screening is recommended when ptosis or dysphagia is diagnosed in adult patients from these populations.
OPMD is confirmed by molecular genetic testing. The diagnostic process proceeds in the following order.
Step 1 — clinical suspicion: combination of ptosis + dysphagia after age 50, family history. Step 2 — PABPN1 gene repeat number analysis: the number of GCG repeats in peripheral blood DNA is analyzed by PCR and capillary electrophoresis. The diagnosis is established when a repeat number of 12 or more is confirmed. This test is commercially available and, with its high sensitivity and specificity, can establish the diagnosis on its own. A repeat number of 11 is borderline and requires further evaluation depending on the clinical situation. Step 3 — muscle biopsy (if needed): performed when genetic testing is unavailable or interpretation of the results is uncertain, or when the phenotype is atypical. Intranuclear inclusions and rimmed vacuoles on Gomori trichrome staining and 8~10 nm tubulofilaments on electron microscopy support the diagnosis.
Assessment of swallowing function: after the diagnosis is established, the presence and severity of aspiration are objectively assessed by videofluoroscopic swallowing study (VFSS) or fiberoptic endoscopic evaluation of swallowing (FEES), and the need for surgical treatment (cricopharyngeal myotomy) or dietary adjustment is determined. Esophageal manometry can also be used as an adjunct.
Ophthalmological assessment: the severity of ptosis is quantified by measuring the margin-reflex distance (MRD1) and the palpebral fissure height (PFH). Corneal exposure and the need for eye drops are assessed.
There is currently no clinically approved disease-modifying therapy for OPMD. Treatment focuses mainly on symptom relief and prevention of complications.
Treatment of ptosis: eyelid surgery is most effective. Levator resection is chosen when some levator function remains, and when levator function is markedly reduced, frontalis suspension is performed so that the eyelid is lifted by the force of the frontalis muscle. After surgery, artificial tears and eye ointment and an eye patch at night are needed to prevent corneal exposure. Because eye movements are normal in OPMD patients, the postoperative risk to the eye is relatively lower than in patients with external ophthalmoplegia.
Treatment of dysphagia: cricopharyngeal myotomy is the most effective surgical treatment for dysphagia in OPMD. It releases impaired relaxation of the cricopharyngeus muscle, easing the passage of food. Endoscopic balloon dilation or botulinum toxin injection can also be performed. Dietary adjustment (consistency modification, small frequent meals), swallowing rehabilitation (training in swallowing postures, the Mendelsohn maneuver) and nutritional supplementation are provided alongside. In severe dysphagia, percutaneous endoscopic gastrostomy (PEG) is considered.
Proximal weakness: function is maintained with physical therapy and strengthening exercises. Occupational therapy, including use of assistive devices.
Treatments under investigation: AAV-based gene therapy (delivery of normal PABPN1 + suppression of the mutant allele by RNAi) is being validated in animal models. Guanabenz (an integrated stress response modulator) has also shown preclinical efficacy. Research toward transition to the clinical trial stage is under way.
OPMD is a myopathy with a relatively slow rate of progression, and with active symptomatic treatment, quality of life can be maintained for a considerable period. Walking ability is preserved throughout life in most patients, and wheelchair dependence is limited to some severe or elderly patients.
The main causes of morbidity are malnutrition and aspiration pneumonia due to dysphagia. Aspiration pneumonia is an important cause of death in OPMD patients, and reducing the risk of aspiration with surgical treatment such as cricopharyngeal myotomy is important for improving prognosis. Appropriate eyelid surgery for ptosis also contributes to improved vision and reduced risk of falls.
The life expectancy of OPMD patients is reported not to differ greatly from that of the general population, but the prognosis is poor when aspiration pneumonia recurs. Regular assessment of swallowing function, nutritional management and monitoring of respiratory function are essential for improving long-term prognosis. In terms of mental health, social isolation and depression due to progressive swallowing and eyelid symptoms may also occur, so psychosocial support should be provided as well.
Fundamental prevention of OPMD is achieved through genetic counseling and genetic testing. Because inheritance is autosomal dominant, children of an affected parent have a 50% probability of carrying the mutation. When there is a family history, PABPN1 gene testing is offered to adult children, and a regular monitoring plan is established according to the results. Preimplantation genetic diagnosis (PGT-M) is technically possible as a way to prevent implantation of potentially affected embryos, but given the adult onset and relatively slow progression of the disease, thorough counseling and ethical discussion are needed for each family.
Secondary prevention (prevention of complications): in confirmed patients, education on aspiration prevention (eating posture, adjustment of food viscosity, small frequent meals) is provided, and swallowing function is assessed every 6 months~1 year to determine the timing of surgical treatment. Oral health care and pneumococcal and influenza vaccination reduce the risk of aspiration pneumonia. Regular ophthalmological examinations prevent complications of corneal exposure and allow early determination of surgical indications. Balanced nutrition and swallowing rehabilitation prevent weight loss and nutritional deficiency.